Market Place
Sourcing Support
Abcuro Announces Participation in Upcoming Investor Conferences
29 Aug 2024 //
BUSINESSWIRE
Abcuro Appoints Sarah Boyce to its Board of Directors
31 Jul 2024 //
BUSINESSWIRE
Abcuro uses $155M series B to push KLRG1 antibody through clinic
17 Aug 2023 //
FIERCE BIOTECH
Abcuro Completes Enrollment of Sentinel Cohort in Phase 2/3 Study of ABC008
31 May 2023 //
BUSINESSWIRE
Abcuro Initiates Registrational Phase 2/3 Study of ABC008
03 Apr 2023 //
BUSINESSWIRE
Abcuro Initiates Phase 1/2 Trial Evaluating ABC008 in Patients
04 Oct 2022 //
BUSINESSWIRE
Abcuro to Present Abstract at ACRC 2021 of ABC008 Body Myositis Phase 1 Data
05 Nov 2021 //
BUSINESSWIRE
Abcuro Appoints Darlene Deptula-Hicks to its Board of Directors
19 Oct 2021 //
BUSINESSWIRE
Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008
06 Oct 2021 //
BUSINESSWIRE
Abcuro and ImaginAb Share Initial Results of Study Using Novel Technology
30 Jun 2021 //
BUSINESSWIRE
Sanofi-backed Abcuro bags $42M to trial KLRG1 immunotherapy
07 Jan 2021 //
FIERCEBIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.